Precision Medicine Quarterly

Fulgent Genetics Announces Strategic Investment in Spatial Genomics

2022-02-25T12:05:13-05:00February 25th, 2022|

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced a strategic investment in Spatial Genomics, Inc. (“Spatial”), a leading developer of sequential fluorescence in situ hybridization (seqFISH) technology. Fulgent Genetics is investing up [...]

Blueprint Medicines Provides 2022 Portfolio Goals Targeting Expanded Precision Therapy Leadership

2022-01-19T19:03:43-05:00January 19th, 2022|

Blueprint Medicines Corporation (NASDAQ: BPMC) outlined upcoming portfolio milestones that are anticipated to extend its position as a leading precision therapy company. "With two precision therapies expanding their global reach across multiple approved indications, four INDs filed from our portfolio in 2021, and a range of clinical data inflection points anticipated over the next [...]

Lantern Pharma Enters into Strategic Collaboration with Deep Lens

2021-09-30T11:36:37-05:00September 30th, 2021|

Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development and Deep Lens, a digital healthcare company focused on enabling faster recruitment of the best-suited cancer patients for clinical trials at the time of [...]

Lifebit raises $60m to make vital biomedical data securely accessible for life changing research worldwide

2021-09-30T11:29:38-05:00September 30th, 2021|

Lifebit Biotech Ltd – the leading precision medicine software company democratising access to biomedical data of governments, biobanks and healthcare providers for research teams worldwide – has raised a $60 million Series B funding round, led by global investment firm Tiger Global Management. Existing investors Eurazeo, Pentech Ventures, and Beacon Capital also participated. Despite [...]

Tempus xF Liquid Biopsy Assay Demonstrates Extensive Analytical and Clinical Validity in npj Precision Oncology Study

2021-07-14T07:59:04-05:00July 14th, 2021|

Tempus, a leader in artificial intelligence and precision medicine, today announced results from validation studies demonstrating the reliable analytical performance of the Tempus|xF liquid biopsy. When validated against methods such as ddPCR, the Roche AVENIO kit, and the Tempus|xT solid tumor assay, xF demonstrated high sensitivity and specificity for calling SNVs, indels, CNVs, and [...]

Novartis and Hewlett Packard Enterprise join forces to advance Novartis global health efforts

2021-07-14T07:56:30-05:00July 14th, 2021|

Novartis and Hewlett Packard Enterprise (HPE) today announced a collaboration that aims to accelerate the use of data and digital technologies within Novartis efforts to reimagine global health and improve access to healthcare and medicines. The collaboration will focus on three global health enablers: identifying and integrating complex data sources related to health; advancing [...]

Dr. Eric Walk Joins PathAI as Chief Medical Officer

2021-07-14T07:53:42-05:00July 14th, 2021|

PathAI, a leading provider of AI-powered technology for advancing pathology research, announced that it has appointed Pathologist and executive leader Eric Walk, MD, FCAP, as Chief Medical Officer. "The PathAI team is excited to welcome Dr. Eric Walk onto our leadership team," said Andrew Beck. "Eric brings decades of experience working in the global [...]

Thermo Fisher Scientific to Acquire Point-of-Care Molecular Diagnostics Provider Mesa Biotech

2021-01-27T07:05:48-05:00January 27th, 2021|

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it has entered into a definitive agreement to acquire Mesa Biotech, Inc., a privately held molecular diagnostic company, for approximately $450 million in cash. Under the terms of the agreement, Thermo Fisher will pay up to an additional $100 million [...]

Delfi Diagnostics Announces $100 Million Series A Financing to Develop a New Class of Early Detection Liquid Biopsy for Multiple Cancers

2021-01-27T07:04:00-05:00January 12th, 2021|

Delfi Diagnostics, Inc., a pioneering developer of a new class of high performance, affordable liquid biopsy tests for early cancer detection, has raised $100 million in Series A funding. The round was led by OrbiMed, with participation from existing investors including Menlo Ventures, Samsara Biocapital, Illumina Ventures, AV8 Ventures, and Windham Venture Partners, and [...]

Leading Diagnostics Companies Join Forces to Establish the Access to Comprehensive Genomic Profiling Coalition (ACGP)

2021-01-27T07:00:15-05:00November 17th, 2020|

Seven leading diagnostics companies and laboratory service providers have formed the Access to Comprehensive Genomic Profiling Coalition (ACGP). The goal of the organization is to collectively advocate for appropriate broad U.S. health insurance coverage of comprehensive genomic profiling (CGP) for patients living with advanced cancer. The current members of ACGP are Exact Sciences (NASDAQ: [...]

Go to Top